hydrazine has been researched along with Leukemia, Myeloid, Acute in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.94) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (12.50) | 29.6817 |
| 2010's | 33 (51.56) | 24.3611 |
| 2020's | 16 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, S; Si, Y; Wang, J; Wang, Y; Yin, X; Yu, L | 1 |
| Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE | 1 |
| Bekker-Jensen, DB; Blume-Jensen, P; Eguchi, A; Emdal, KB; Itzykson, R; Kazi, JU; Masson, K; Nilsson, H; Olsen, JV; Palacio-Escat, N; Puissant, A; Rönnstrand, L; Saez-Rodriguez, J; Wigerup, C | 1 |
| Grosicki, S; Lawniczek, T; Mittelman, M; Platzbecker, U; Selleslag, D; Zhu, Z | 1 |
| Chavez, J; Cubitt, CL; Dawson, JL; Komrokji, R; Lancet, JE; List, AF; Padron, E; Sallman, DA; Shah, BD; Sullivan, DM; Sweet, K; Turner, JG; Zhou, J | 1 |
| Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Prasad, V; Tao, D | 1 |
| Advani, A; Barot, SV; Carraway, HE; Kalaycio, M; Kerr, C; Kuzmanovic, T; Lee, S; Lichtin, A; Maciejewski, JP; Patel, BJ; Patel, S; Przychodzen, BP; Radivoyevitch, T; Sekeres, MA; Thota, S | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| Artz, AS; Bishop, M; Cooperrider, JH; Fulton, N; Kosuri, S; Larson, RA; Liu, H; Stock, W | 1 |
| Babushok, DV; Sun, L | 1 |
| Cerny, J; Lazarus, HM; Litzow, M; Rowe, JM; Rybka, W; Strickland, SA; Tallman, MS; Wang, XV | 1 |
| Amberg, S; Bokemeyer, C; Christine Wilke, A; Chromik, J; Deppermann, U; Fiedler, W; Ganser, A; Heuser, M; Janning, M; Kebenko, M; Kranich, AL; Modemann, F; Schlipfenbacher, V; Serve, H; Theile, S; Thol, F | 1 |
| Abdel-Wahab, O; Alvarez, K; Chung, SS; Gönen, M; Klimek, VM; Mi, X; Paffenholz, SV; Park, JH; Penson, AV; Rampal, RK; Sen, F; Sigler, A; Stein, EM; Tallman, MS; Taylor, J | 1 |
| Albitar, M; Barranta, E; Calvo, KR; Dunbar, CE; Feng, X; Giudice, V; Groarke, E; Gutierrez-Rodrigues, F; Kajigaya, S; Lotter, J; Olnes, MJ; Parikh, AR; Patel, BA; Scheinberg, P; Shalhoub, R; Townsley, DM; Vicente, A; Weinstein, B; Winkler, T; Wu, CO; Young, NS | 1 |
| Acuña-Cruz, E; Barragán, E; Bergua, JM; Boluda, B; Cano-Ferri, I; Martín-Herreros, B; Martínez Sánchez, MP; Martínez-Cuadrón, D; Martínez-López, J; Megías-Vericat, JE; Montesinos, P; Rodríguez-Veiga, R; Sanz, M; Sargas, C; Sempere, A; Serrano, A; Suárez-Varela, S; Torrent, A; Torres-Miñana, L; Vives, S | 1 |
| Andreeff, M; Baz, R; Carlson, R; Gabrail, N; Garzon, R; Gutierrez, M; Kashyap, T; Kauffman, M; Klebanov, B; Mau-Sorensen, PM; Rashal, T; Saint-Martin, JR; Savoie, L; Savona, M; Shacham, S; Stone, R; Unger, TJ; Wagner-Johnston, N; Yee, K | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| He, Z; Hu, Y; Huang, P; Li, Y; Liu, J; Liu, P; Lu, W; Wang, J; Wen, S | 1 |
| Beck, JF; Becker, S; Ebert, F; Lauterjung, ML; Marx, C; Sonnemann, J; Zimmermann, M | 1 |
| Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z | 1 |
| Shastri, A; Verma, AK | 1 |
| Brunetti, L; Buckley, DL; Falini, B; Gionfriddo, I; Goodell, MA; Gundry, MC; Guzman, AG; Huang, YH; Kornblau, SM; Lin, CY; Martelli, MP; Mezzasoma, F; Milano, F; Nabet, B; Ramabadran, R; Sorcini, D; Sportoletti, P | 1 |
| Edwards, H; Ge, Y; Lin, H; Liu, S; Luedtke, DA; Su, Y; Taub, JW; Wang, Y | 1 |
| Buckstein, R | 1 |
| Estey, EH; Percival, MM | 1 |
| Dama, P; Fulton, N; Kline, J; Liu, H; Tang, M | 1 |
| Cardamone, D; Frey, NV; Glaser, L; Kricka, LJ; Milone, MC | 1 |
| Pathak, S; Roth, M; Steidl, U; Verma, A | 1 |
| Bhagat, T; Braunschweig, I; Roth, M; Schinke, C; Steidl, U; Tamari, R; Verma, A; Will, B | 1 |
| Bearss, D; Bhalla, KN; Devaraj, SG; Fiskus, W; Iyer, SP; Liu, K; Portier, BP; Shah, B; Sharma, S | 1 |
| Amin, S; Colledge, AL; Dick, TE; Fox, TE; Hengst, JA; Kale, VP; Kester, M; Loughran, TP; Sharma, A; Sung, SS; Wang, HG; Yun, JK | 1 |
| Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X | 1 |
| Adamia, S; Berezovskaya, A; Chen, WC; Christie, AL; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Kentsis, A; Klebanov, B; Kung, AL; Landesman, Y; Le, BT; Letai, A; Look, AT; Mansour, MR; Montero, J; Ng, CE; Reed, C; Rodig, SJ; Shacham, S; Stone, RM; Wang, JC | 1 |
| Abboud, C; Araujo, S; Bennett, J; Chan, G; Chen, CY; Cheng, G; Chiou, TJ; Dougherty, S; Feigert, J; Giagounidis, A; Gorin, NC; Götze, K; Greenberg, P; Jang, JH; Johnson, B; Kambhampati, S; Kamel, YM; Kim, YJ; Lee, JH; Lyons, R; Mannino, F; Platzbecker, U; Ruggeri, M; Santini, V; Stone, N; Verma, A; Wong, RS; Yeh, SP | 1 |
| Brandwein, JM; Chow, S; Gupta, V; Hedley, D; Sanfelice, D; Schimmer, AD; Schuh, AC; Seftel, MD; Shamas-Din, A; Yee, KW | 1 |
| Adams, DF; Sellers, TS | 1 |
| Baloglu, E; Berezovskaya, A; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Landesman, Y; Look, AT; Senapedis, W; Shacham, S; Stone, RM; Wang, JC | 1 |
| Bhatnagar, B; Blum, W; Dorrance, AM; Garzon, R; Kashyap, T; Kauffman, M; Lai, TH; Landesman, Y; McNeil, B; Meng, X; Ranganathan, P; Sampath, D; Shacham, S; Yu, X | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Adane, B; Alvarez-Calderon, F; D'Alessandro, A; DeGregori, J; Gregory, MA; Hansen, KC; Jordan, CT; Kim, J; Kumar, A; Kumar, V; Nemkov, T; Pollyea, DA; Rozhok, AI; Serkova, NJ; Tan, AC; Wempe, MF | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Gore, SD | 1 |
| Adams, JA; Liu Yin, JA; Morris, KL | 1 |
| Giles, FJ | 1 |
| Albitar, M; Boskovic, D; Brandwein, J; Cahill, A; DeAngelo, D; Giles, F; Kell, J; O'Brien, S; Pigneux, A; Robak, T; Seiter, K; Staib, P; Stock, W; Stuart, R; Tallman, M; Thomas, X; Vey, N | 1 |
| Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B | 1 |
| Albitar, MX; Cahill, AL; Deangelo, DJ; Giles, FJ; Karsten, V; Kell, J; O'Brien, SM; Pigneux, A; Schiller, GJ; Solomon, S; Stuart, RK; Vey, N | 1 |
| Chen, H; Deisseroth, A; Farrell, A; He, K; Justice, R; Kane, R; Pazdur, R; Sridhara, R | 1 |
| Giles, F; Vey, N | 1 |
| Aivado, M; Chadderton, A; Erickson-Miller, CL; Kirchner, J; May, R; Payne, P | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Kuter, DJ | 1 |
| Amin, S; Hori, T; Hu, CD; Kester, M; Khan, O; Park, S; Sharma, AK; Takahashi, Y; Wang, HG; Young, MM; Yun, J; Zhang, J | 1 |
| Carroll, M; Gewirtz, AM; Kalota, A; Sugita, M | 1 |
| FREI, E; FREIREICH, EJ; KARON, M | 1 |
| HOLLAND, JR; REGELSON, W | 1 |
| Advani, A; Albitar, M; Bilgrami, SF; Cahill, A; Daenen, SM; Faderl, S; Ferrant, A; Giles, F; Kantarjian, H; Karp, J; Karsten, V; Khan, KD; Mufti, G; O'Brien, S; Ravandi, F; Rizzieri, D; Roboz, G; Verhoef, G; Vey, N; Wijermans, P | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Akin, DT; Barton, JC; Gilbert, CS; Kinkade, JM; Parmley, RT | 1 |
| Bricteux, N; Focan, C; Hugues, J; Jardon-Jeghers, C | 1 |
| Böhnel, J; Stacher, A | 1 |
| Clément, F | 1 |
| Hamilton, WC; La Placa, SJ | 1 |
8 review(s) available for hydrazine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Topics: Antineoplastic Agents; Benzoates; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Hematologic Diseases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Laromustine (cloretazine).
Topics: Aged; Animals; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Hydrazines; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides; Treatment Outcome | 2010 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
What is the potential for thrombopoietic agents in acute leukemia?
Topics: Adult; Benzoates; Blood Platelets; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Hydrazines; Leukemia, Myeloid, Acute; Molecular Mimicry; Platelet Count; Polyethylene Glycols; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Remission Induction; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Time Factors | 2011 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
17 trial(s) available for hydrazine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis.
Topics: Adult; Aged; Humans; Hydrazines; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Systematic Reviews as Topic; Triazoles | 2021 |
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles | 2022 |
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2020 |
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult | 2020 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning; Triazoles | 2020 |
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Recurrence; Salvage Therapy; Triazoles | 2020 |
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Patient Safety; Prognosis; Survival Rate; Triazoles | 2020 |
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Triazoles; Vidarabine | 2021 |
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Topics: Adult; Blast Crisis; Bone Marrow Cells; Disease-Free Survival; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Triazoles | 2017 |
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Topics: Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Placebos; Pyrazoles; Safety; Thrombocytopenia | 2018 |
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Drug Resistance, Neoplasm; Female; Galectins; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; T-Lymphocyte Subsets; Treatment Failure; Triazoles | 2019 |
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Double-Blind Method; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Treatment Outcome | 2015 |
A phase I study of elesclomol sodium in patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2016 |
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides; Young Adult | 2009 |
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comorbidity; Europe; Female; Gene Expression Regulation, Leukemic; Heart Diseases; Humans; Hydrazines; Infusions, Intravenous; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Liver Diseases; Lung Diseases; Male; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Treatment Outcome; United States | 2010 |
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Chemical; Prognosis; Remission Induction; Risk; Sulfonamides; Time Factors; Treatment Outcome | 2007 |
39 other study(ies) available for hydrazine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hydrazines; Leukemia, Myeloid, Acute; Proteome; Proto-Oncogene Proteins c-akt; Triazoles; Tumor Suppressor Protein p53 | 2022 |
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukopenia; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2023 |
Concerning survival signal for eltrombopag in MDS/AML.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles | 2020 |
Distinctive and common features of moderate aplastic anaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anemia, Aplastic; Autoimmune Diseases; Benzoates; Blood Transfusion; Bone Marrow; Child; Child, Preschool; Clonal Evolution; Combined Modality Therapy; Danazol; Disease Management; Disease Progression; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrazoles; Severity of Illness Index; Young Adult | 2020 |
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening | 2020 |
A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Consolidation Chemotherapy; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles | 2020 |
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
Topics: Benzoates; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles | 2020 |
Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Synergism; Energy Metabolism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Demethylases; Histones; HL-60 Cells; Humans; Hydrazines; Leukemia, Myeloid, Acute; Methylation; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Morpholines; Proto-Oncogene Proteins c-bcl-2; Pyridones; Sulfonamides; Time Factors; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
Topics: Animals; Histone Demethylases; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice; Neoplasm Proteins; Sulfonamides; THP-1 Cells; Xenograft Model Antitumor Assays | 2018 |
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk; Thrombocytopenia | 2018 |
Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Topics: Aged; Animals; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Down-Regulation; Exportin 1 Protein; Female; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mutation; Nuclear Proteins; Nucleophosmin; Proteolysis; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
Topics: Adult; Aged; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles | 2018 |
Eltrombopag use in higher risk myeloid cancers: fitting a square "pag" into a round hole?
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Risk | 2019 |
Eltrombopag and serum of a different hue.
Topics: Aged; Aged, 80 and over; Benzoates; Bilirubin; Humans; Hydrazines; Hydrogen-Ion Concentration; Leukemia, Myeloid, Acute; Pigmentation; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2013 |
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Clonal Evolution; Female; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Megakaryocyte Progenitor Cells; Middle Aged; Myelodysplastic Syndromes; Pyrazoles; Thalidomide; Thrombopoiesis | 2014 |
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Topics: Animals; Apoptosis; Cells, Cultured; Co-Repressor Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Histone Acetyltransferases; Histone Demethylases; Histones; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Nerve Tissue Proteins; Nucleophosmin; RNA, Small Interfering; Stem Cells; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.
Topics: Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Hydrazines; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Pyrazoles; U937 Cells | 2015 |
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
Topics: Animals; Exportin 1 Protein; Humans; Hydrazines; Immunosuppression Therapy; Karyopherins; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Receptors, Cytoplasmic and Nuclear; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method.
Topics: Adult; Azo Compounds; Benzoates; Bilirubin; Color; Coloring Agents; Diagnosis, Differential; Hematinics; Humans; Hydrazines; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Osmolar Concentration; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Serum; Spectrophotometry; Thrombocytopenia | 2016 |
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Blast Crisis; Carcinogenesis; Exportin 1 Protein; Hematopoietic Stem Cells; Heterografts; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Receptors, Cytoplasmic and Nuclear; Triazoles | 2017 |
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Proto-Oncogene Proteins c-myc; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Topoisomerase II Inhibitors; Triazoles | 2016 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzothiazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Glucosephosphate Dehydrogenase; Humans; Hydrazines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Middle Aged; Oxidation-Reduction; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Small Interfering; Signal Transduction; Survival Analysis; Xenograft Model Antitumor Assays | 2016 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Leukemia, Myeloid, Acute; Sulfonamides | 2009 |
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Animals; Apoptosis; Benzoates; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Hematopoiesis; Humans; Hydrazines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Megakaryocytes; Mice; Mice, Inbred NOD; Myelodysplastic Syndromes; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Xenograft Model Antitumor Assays | 2009 |
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Female; Humans; Hydrazines; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sulfonamides | 2010 |
Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
Topics: Base Sequence; Benzoates; Cell Line, Tumor; Cell Proliferation; DNA Primers; Humans; Hydrazines; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Proteins; Caspase 3; Caspase 8; Cell Membrane; Cell Survival; Cells, Cultured; Death Domain Receptor Signaling Adaptor Proteins; Enzyme Activation; Fas-Associated Death Domain Protein; Gene Knockout Techniques; Heat-Shock Proteins; Humans; Hydrazines; Leukemia, Myeloid, Acute; Lysosomal Membrane Proteins; Mice; Microtubule-Associated Proteins; Mitochondria; Phosphotransferases (Alcohol Group Acceptor); Protein Binding; Protein Multimerization; Protein Transport; Pyrazoles; Sequestosome-1 Protein; Tumor Cells, Cultured; Ubiquitin-Conjugating Enzymes | 2012 |
Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
Topics: Benzoates; Cell Line, Tumor; Cell Survival; Humans; Hydrazines; Leukemia, Myeloid, Acute; Pyrazoles; Receptors, Thrombopoietin | 2013 |
Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia.
Topics: Amidines; Antineoplastic Agents; Humans; Hydrazines; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoguazone; Pyruvaldehyde | 1962 |
Clinical experience with methylglyoxal bis (guanylhydrazone) dihydrochloride: a new agent with clinical activity in acute myelocytic leukemia and the lymphomas.
Topics: Antineoplastic Agents; Humans; Hydrazines; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Pyruvaldehyde | 1963 |
Cytochemistry and ultrastructural morphometry of cultured HL60 myeloid leukemia cells.
Topics: 3,3'-Diaminobenzidine; Cells, Cultured; Cytoplasmic Granules; Eosinophils; Golgi Apparatus; Histocytochemistry; Humans; Hydrazines; Leukemia, Myeloid, Acute | 1987 |
[Hodgkin's disease complicated by myeloblastic leukosis].
Topics: Adult; Biopsy; Hodgkin Disease; Humans; Hydrazines; Leukemia, Myeloid, Acute; Lymph Nodes; Male; Mechlorethamine; Methylprednisolone; Radiography; Vinblastine; Vincristine | 1973 |
[On the effect of a cytostatic of the methylhydrazine group on malignant hemoblastomas].
Topics: Adult; Aged; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Hydrazines; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphatic Diseases; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melanoma | 1966 |
[Therapy of malignant hemopathies].
Topics: Female; Hematologic Diseases; Humans; Hydrazines; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Prednisone | 1966 |
The crystal and molecular structure of an anti-leukemia drug: methylglyoxal bisguanylhydrazone dihydrochloride monohydrate, C5N8H12. 2HC1. H2O. neutron and x-ray diffraction studies.
Topics: Antineoplastic Agents; Chemical Phenomena; Chemistry; Humans; Hydrazines; Leukemia, Myeloid, Acute; Neutrons; X-Ray Diffraction | 1968 |